Optimizing Y90 Therapy for Radiation Lobectomy

Part of paid clinical trials in Jacksonville, Florida.

Sponsor
Northwestern University
Study ID
NCT04390724
Status
Recruiting

Conditions

  • Adult Primary Liver Cancer
  • HCC
  • Metastatic Cancer
  • Resection
  • Transplant

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Y90 radioembolization — DEVICE
    Patients with HCC who are eligible to receive standard-of-care Y90 radioembolization and are hepatic resection candidates with inadequate future liver remnant

Study Details

HCC resection candidates with inadequate future liver remnant will be enrolled in this study. They will be treated with Y90 radioembolization to help grow the liver enough to undergo liver resection. There will be 2 Patient Groups. The first group of patients will be treated with Y90 dose and embolic load as per standard-of-care. The second group of patients will be treated with the optimal Y90 dose and embolic load found in Patient Group 1.

Key Dates

Start date
Jul 17, 2020
Status verified
Jul 2025
Primary completion
Jul 31, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
104 participants (estimated)

Arms

  • Arm: Patient Group 1: Y90 Standard-of-Care
    The first group of patients will be treated with Y90 dose and embolic load as per standard-of-care
  • Arm: Patient Group 2: Y90 Dose determined by results from Group 1
    The second group of patients will be treated with the optimal Y90 dose and embolic load found in Patient Group 1

Primary Outcome Measure

Patient Group 1: Y90 Glass Microspheres [ Time Frame: 2 years ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Mayo ClinicJacksonvilleFlorida32224-
Northwestern UniversityChicagoIllinois60611
Robert Lewandowski, MD
312-695-9121
Kristie Kennedy, MA
312-695-4023
Robert Lewandowski, MD (PRINCIPAL_INVESTIGATOR)
Jeremy Collins, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Jacksonville, FL

By condition

Related Studies